May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Treatment of Choroidal Neovascularization With an 8-Mer Peptide Derived From the Uroplasminogen Activator System
Author Affiliations & Notes
  • H.J. Koh
    Ophthalmology, Shiley Eye Center, La Jolla, CA, United States
  • K. Bessho
    Ophthalmology, Shiley Eye Center, La Jolla, CA, United States
  • L. Cheng
    Ophthalmology, Shiley Eye Center, La Jolla, CA, United States
  • D. Bartsch
    Ophthalmology, Shiley Eye Center, La Jolla, CA, United States
  • T.R. Jones
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • G. Bergeron-Lynn
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • W.R. Freeman
    Angstrom Pharmaceuticals, San Diego, CA, United States
  • Footnotes
    Commercial Relationships  H.J. Koh, None; K. Bessho, None; L. Cheng, None; D. Bartsch, None; T.R. Jones, Angstrom Pharmaceuticals P; G. Bergeron-Lynn, None; W.R. Freeman, None.
  • Footnotes
    Support  in part by research to prevent blindness and unrestricted donations
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 3918. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H.J. Koh, K. Bessho, L. Cheng, D. Bartsch, T.R. Jones, G. Bergeron-Lynn, W.R. Freeman; Treatment of Choroidal Neovascularization With an 8-Mer Peptide Derived From the Uroplasminogen Activator System . Invest. Ophthalmol. Vis. Sci. 2003;44(13):3918.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: CNV is the major cause of severe vision loss in AMD and is an important cause of vision loss in other diseases. Anti-angiogenesis therapies have focused on MMP inhibition and VEGF inhibition. We hypothesized that a peptide fragment derived from the uPA-uPAR system, which has been shown to be anti-angiogenic and anti-migratory would have a therapeutic effect in a rat model of laser induced CNV and that this inhibition would occur downstream from VEGF in the angiogenesis cascade. Methods:Forty Brown Norway rats received 8 spots of diode laser treatment in one eye applied in a circle around the optic nerve of sufficient intensity to cause a bubble and rupture of Bruch’s membrane. Ten rats were treated with subcutaneous peptide (200mg/kg/day) and 10 with PBS injections. Two weeks and 7 weeks after induction of CNV, the eyes were studied with confocal FA and ICG angiography; CNV was also confirmed histopathologically. An additional 20 eyes were treated as part of a high dose regimen; In these eyes, the peptide was administered at a dose of 400 mg/kg/day, whereas double amount of PBS injected in their control. Results: At the 200 mg/kg/day dose, the incidence of CNV, defined angiographically, was 31.4 % in the treatment group vs. 50.6 % in the control group. This corresponded to a 37.9% reduction in induced CNV (P= 0.03). At the 400 mg/kg/day dose, the incidence of CNV was 13.4% in the treatment group vs. 44.7% in the control group. This corresponded to a 70.0% reduction in induced CNV (P=0.0124). There was no evidence of adverse effects of the compound. Conclusion:The 8-mer uPA fragment given subcutaneously (or potentially by other routes) may be a good candidate for the treatment of CNV in patients with AMD. Further studies to characterize the ocular pharmacokinetics and effect on normal tissues and to determine the maximal dose needed for treatment should be performed.

Keywords: age-related macular degeneration • choroid: neovascularization • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×